Median Technologies SA announced that the company is expanding its portfolio of services with Imaging Lab, a new entity whose mission is to leverage AI, data mining, and radiomics technologies to exploit imaging data from clinical trials in oncology. The creation of Imaging Lab materializes the convergence of iCRO's activities for image management in the development of new oncologic drugs and iBiopsy®'s activities for the development of software as medical device targeting early diagnosis of cancers, especially lung cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3 EUR | -9.09% | -12.92% | -36.84% |
2023 | European Investment Bank OKs Median Technologies' Draw Down of Final EUR8.5 Million Loan Tranche | MT |
2023 | Median: final tranche of EIB loan approved | CF |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.84% | 58.85M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- ALMDT Stock
- News Median Technologies
- Median Technologies SA Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials